Journal of Gambling Studies

, Volume 25, Issue 3, pp 425–431 | Cite as

Impulse Control Disorder Behaviors Associated with Pramipexole Used to Treat Fibromyalgia

  • Andrew J. HolmanEmail author
Original Paper


Objective: Compulsivity has been associated with use of dopamine agonists used to treat Parkinson’s disease (PD). Increasing use of these agents to treat fibromyalgia (FM) raises concern for this unexpected toxicity in a new group of patients. This is the first report of compulsive gambling and shopping among patients taking dopamine agonists for treatment of FM. Design: A retrospective chart review of all patients in a large, active FM research practice was used to identify compulsivity associated with dopamine agonists and describe its remission following dug withdrawal. Results: Of 3006 patients with FM treated between 2002 and 2006, 1356 had taken ≥1 dose of a dopamine agonist ( >95% pramipexole). Twenty-one (3 male, 18 female) were identified with compulsive gambling (33%), shopping (40%) or both (27%) after taking a 4.5 mg mean dose of pramipexole at bedtime for 14.4 ± 14.9 months. Compulsivity resolved in 3–10 days for 19 of 21 patients and by 3 months for all following a monitored, compulsory tapered discontinuation over 7 days. Conclusions: While biologic aspects of PD and FM differ considerably, compulsive gambling and shopping have become important, yet unexpected concerns related to use of dopamine agonists for patients with FM and their treating clinicians.


Pramipexole Dopamine Fibromyalgia Compulsivity Gambling ICD 


  1. Aiken, C. B. (2007). Pramipexole in psychiatry: A systemic review of the literature. The Journal of Clinical Psychiatry, 68(8), 1230–1236.PubMedCrossRefGoogle Scholar
  2. Carville, S. F., Arendt-Nielsen, S., Bliddal, H., Blotman, F., Branco, J. C., Buskila, D., et al. (2008). EULAR evidenced based recommendations for the management of fibromyalgia syndrome. Annals of the Rheumatic Diseases, 67(4), 536–541. doi: 10.1136/ard.2007.071522.PubMedCrossRefGoogle Scholar
  3. da Silva Lobo, D. S., Vallada, H. P., Knight, J., et al. (2007). Dopamine genes and pathological gambling in discordant sib-pairs. Journal of Gambling Studies, 23(4), 421–433. doi: 10.1007/s10899-007-9060-x.PubMedCrossRefGoogle Scholar
  4. Dodd, M. L., Klos, K. J., Bower, J. H., Geda, Y. E., Josephs, K. A., & Ahlskog, J. E. (2005). Pathological gambling caused by drugs used to treat Parkinson’s disease. Archives of Neurology, 62, 1–5. doi: 10.1001/archneur.62.9.noc50009.CrossRefGoogle Scholar
  5. Evans, A. H., & Butzkueven, H. (2007). Dopamine agonist-induced pathological gambling in restless legs syndrome due to multiple sclerosis. Movement Disorders, 22(4), 590–591. doi: 10.1002/mds.21303.PubMedCrossRefGoogle Scholar
  6. Gallagher, D. A., O’Sullivan, S. S., Evans, A. H., Lees, A. J., & Schrag, A. (2007). Pathological gambling in Parkinson’s disease: Risk factors and differences from dopamine dysregulation. An analysis of published case series. Movement Disorders, 22(12), 1757–1763. doi: 10.1002/mds.21611.PubMedCrossRefGoogle Scholar
  7. Grant, J. E. (2008). Impulse control disorders: A clinician’s guide to understanding and treating behavioral addictions. New York: WW Norton.Google Scholar
  8. Grosset, K. A., Macphee, G., Pal, G., et al. (2006). Problematic gambling on dopamine agonists: Not such a rarity. Movement Disorders, 21(12), 2206–2208. doi: 10.1002/mds.21110.PubMedCrossRefGoogle Scholar
  9. Holman, A. J. (2003a). Ropinirole, a dopamine agonist, for refractory fibromyalgia: Preliminary observations. Journal of Clinical Rheumatology; Practical Reports on Rheumatic & Musculoskeletal Diseases, 9(4), 277–279. doi: 10.1097/01.rhu.0000081264.26484.e5.Google Scholar
  10. Holman, A. J. (2003b). Pramipexole and fibromyalgia: Promise and precaution. Journal of Rheumatology, 30(12), 2733. letter.PubMedGoogle Scholar
  11. Holman, A. J. (2004). Treatment of fibromyalgia with the dopamine agonist ropinirole a 14-week double-blind, pilot, randomized controlled trial with 14-week blinded extension. Arthritis and Rheumatism, 50(9), S698. abstract.Google Scholar
  12. Holman, A. J., & Myers, R. R. (2005). A randomized, double-blind, placebo-controlled trial of pramipexole, a dopamine agonist, in patients with fibromyalgia receiving concomitant medications. Arthritis and Rheumatism, 52(8), 2495–2505. doi: 10.1002/art.21191.PubMedCrossRefGoogle Scholar
  13. Holman, A. J., Neiman, R. A., & Ettlinger, R. E. (2004). Preliminary efficacy of the dopamine against, pramipexole for fibromyalgia: The first, open label, multicenter experience. Journal of Musculoskeletal Pain, 12(1), 69–74. doi: 10.1300/J094v12n01_10.CrossRefGoogle Scholar
  14. Mamikonyan, E., Siderowf, A. D., Duda, J. E., Potenza, M. N., Horn, S., Stern, M. B., et al. (2008). Long-term follow-up of impulse control disorders in Parkinson’s disease. Movement Disorders, 23(1), 75–80. doi: 10.1002/mds.21770.PubMedCrossRefGoogle Scholar
  15. McIntyre, R. S., McElroy, S. L., Konarski, J. Z., Soczynska, J. K., Wilkins, K., & Kennedy, S. H. (2007). Problem gambling in bipolar disorder: Results of the Canadian Community Health Survey. Journal of Affective Disorders, 102(1–3), 27–34. doi: 10.1016/j.jad.2006.12.005.PubMedCrossRefGoogle Scholar
  16. Ondo, W. G., & Lai, D. (2008). Predictors of impulsivity and reward seeking behavior with dopamine agonists. Parkinsonism & Related Disorders, 14(1), 28–32. doi: 10.1016/j.parkreldis.2007.05.006.CrossRefGoogle Scholar
  17. Quickfall, J., & Suchowersky, O. (2007). Pathological gambling associated with dopamine agonist use in restless legs syndrome. Parkinsonism & Related Disorders, 13(8), 535–536. doi: 10.1016/j.parkreldis.2006.10.001.CrossRefGoogle Scholar
  18. Singh, A., Kandimala, G., Dewey, R. B., Jr, & O’Suilleabhain, P. (2007). Risk factors for pathological gambling and other compulsions among Parkinson’s disease patients taking dopamine agonists. Journal of Clinical Neuroscience, 14(12), 1178–1181. doi: 10.1016/j.jocn.2007.01.009.PubMedCrossRefGoogle Scholar
  19. Wood, P. B. (2004). Stress and dopamine: Implications for the pathophysiology of chronic widespread pain. Medical Hypotheses, 62, 420–424. doi: 10.1016/j.mehy.2003.10.013.PubMedCrossRefGoogle Scholar
  20. Wood, P. B. (2006). Mesolimbic dopaminergic mechanisms and pain control. Pain, 120, 230–234. doi: 10.1016/j.pain.2005.12.014.PubMedCrossRefGoogle Scholar
  21. Wood, P. B., Patterson, J. C., Sunderland, J. J., Tainter, J. H., Glabus, M. F., & Lilien, D. L. (2007). Reduced presynaptic dopamine activity in fibromyalgia syndrome demonstrated with positron emission tomography: A pilot study. Pain, 8(1), 51–58. doi: 10.1016/j.jpain.2006.05.014.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  1. 1.Pacific Rheumatology ResearchRentonUSA

Personalised recommendations